Compare BEPC & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BEPC | TWST |
|---|---|---|
| Founded | 2019 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.2B |
| IPO Year | 2019 | 2018 |
| Metric | BEPC | TWST |
|---|---|---|
| Price | $32.75 | $94.21 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 8 |
| Target Price | $39.75 | ★ $46.88 |
| AVG Volume (30 Days) | 1.3M | ★ 1.9M |
| Earning Date | 05-01-2026 | 05-04-2026 |
| Dividend Yield | ★ 4.46% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $376,572,000.00 |
| Revenue This Year | $78.11 | $18.91 |
| Revenue Next Year | N/A | $15.07 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 20.32 |
| 52 Week Low | $32.76 | $23.30 |
| 52 Week High | $45.18 | $105.47 |
| Indicator | BEPC | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 27.28 | 55.61 |
| Support Level | N/A | $87.57 |
| Resistance Level | $41.27 | $105.47 |
| Average True Range (ATR) | 1.05 | 6.78 |
| MACD | -0.20 | -1.23 |
| Stochastic Oscillator | 6.74 | 41.12 |
Brookfield Renewable is a globally diversified, multitechnology owner and operator of clean energy assets. The company's portfolio consists of hydroelectric, wind, solar, and storage facilities in North America, South America, Europe, and Asia, and totals over 40 gigawatts of installed capacity. Brookfield Renewable invests in assets directly, as well as with institutional partners, joint venture partners, and through other arrangements. The company offers two separate listings for investors: Brookfield Renewable Partners LP and Brookfield Renewable Corp.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.